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S UMMA R Y
S E T T I NG : Vitamin D deficiency is common in African
adults with tuberculosis (TB), and may be exacerbated
by the metabolic effects of anti-tuberculosis drugs and
antiretroviral therapy (ART). It is unclear whether
vitamin D deficiency influences response to anti-
tuberculosis treatment.
OB J E C T I V E S : To describe risk factors for baseline
vitamin D deficiency in Malawian adults with pulmo-
nary TB, assess the relationship between serum 25-
hydroxy vitamin D (25[OH]D) concentration and
treatment response, and evaluate whether the adminis-
tration of anti-tuberculosis drugs and ART is deleterious
to vitamin D status during treatment.
DE S I GN : A prospective longitudinal cohort study.
R E SU LT S : The median baseline 25(OH)D concentra-
tion of the 169 patients (58% human immunodeficiency
virus [HIV] infected) recruited was 57 nmol/l; 47 (28%)
had vitamin D deficiency (,50 nmol/l). Baseline
25(OH)D concentrations were lower during the cold
season (P , 0.001), with food insecurity (P¼ 0.034) or
in patients who consumed alcohol (P ¼ 0.019). No
relationship between vitamin D status and anti-tubercu-
losis treatment response was found. 25(OH)D concen-
trations increased during anti-tuberculosis treatment,
irrespective of HIV status or use of ART.
CO N C L U S I O N S : Vitamin D deficiency is common
among TB patients in Malawi, but this does not
influence treatment response. Adverse metabolic effects
of drug treatment may be compensated by the positive
impact of clinical recovery preventing exacerbation of
vitamin D deficiency during anti-tuberculosis treatment.
K E Y WORD S : treatment failure; relapse; seasonality;
HIV; antiretroviral therapy
TUBERCULOSIS (TB) remains a major public health
problem in Malawi. In 2013, 156 cases were notified
per 100 000 population, and 56% of TB patients
were human immunodeficiency virus (HIV) co-
infected.1 Despite the consistent implementation of
World Health Organization (WHO) approved treat-
ment, successful outcomes from the Malawian
National Tuberculosis Control Programme (NTP)
have remained at ~80% for the last decade.1,2 Risk
factors contributing to poor outcomes for individual
patients, and strategies to ameliorate these risk
factors, have not yet been identified.
Previous work has shown that vitamin D deficiency
is more common in Malawian adults with TB than in
the general hospital population.2,3 The most active
vitamin D metabolite is 1,25 hydroxycholecalciferol
(1,25[OH]D), an immunologically active hormone
that stimulates antimycobacterial activity in vitro.4–9
Although clinical trials have not shown improved
clinical outcomes when standard anti-tuberculosis
treatment is augmented with oral vitamin D,10–12
target serum levels of vitamin D for a clinically
significant effect are unknown, and some researchers
advocate alternative dosing strategies or describe
benefits for particular patient groups.10 A single study
from Tanzania reported that low baseline serum
vitamin D concentrations were associated with poor
clinical outcomes.13
Furthermore, some components of anti-tuberculo-
sis treatment and antiretroviral therapy (ART) may
pharmacologically lower serum concentrations of
useful vitamin D metabolites. Vitamin D is synthe-
sised in the skin after exposure to sunlight or
consumed in the diet, then converted by sequential
hydroxylation into 25(OH)D and 1,25(OH)D. Isoni-
azid (INH) inhibits both hydroxylation steps,14 while
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rifampicin (RMP) induces alternative enzyme activity
to degrade 25(OH)D into a waste product.15 Com-
bined RMP and INH treatment may reduce serum
concentrations of useful vitamin D metabolites by
23–34%.15 Some ART drugs, such as efavirenz
(EFV), have also been associated with vitamin D
deficiency.16 It is therefore possible that low baseline
vitamin D levels are further compromised by drug
therapy in HIV-TB co-infected populations.
The present study aimed to describe risk factors for
baseline vitamin D deficiency in a cohort of Mala-
wian adults with pulmonary TB, assess the relation-
ship between 25(OH)D concentrations and treatment
response, and evaluate whether the administration of
RMP, INH and ART is deleterious to vitamin D status
during treatment.
METHODS
Patient recruitment and follow-up
This work was nested within a longitudinal cohort
study of response to anti-tuberculosis treatment
among Malawian adults at Queen Elizabeth Central
Hospital in Blantyre, Malawi, from 2010 to 2012.
Consenting adults with sputum smear-positive pul-
monary TB graded ‘þþ’ or ‘þþþ’ for acid-fast bacilli
(AFB) on Ziehl-Neelsen (ZN) stained slides were
eligible.17 Exclusion criteria included haemoglobin
,6 g/dl, creatinine .177 lmol/l, total bilirubin .51
lmol/l, alanine transaminase.200 international units
(IU)/l, clinical status suggestive of imminent mortality
(WHO performance score 418), pregnancy, anti-
tuberculosis treatment in the last 5 years, corticoste-
roid therapy or baseline resistance to RMP and INH.
All patients underwent chest radiograph (CXR) and
point-of-care HIV serology. ART was available
according to national protocols.19,20 Anti-tuberculo-
sis treatment was prescribed according to NTP
guidelines:21 RMP, INH, pyrazinamide and ethambu-
tol were administered for 8 weeks, followed by RMP
and INH for 16 weeks. Follow-up continued for 1
year after end of treatment to incorporate relapse rates
into final outcomes.
Patients with negative TB sputum cultures from the
end of treatment onwards or who stopped coughing
and remained well until study discharge were defined
as ‘stable cures’. Those who were culture-positive at
the end of treatment were ‘failures’. Those who were
culture-negative at the end of treatment, but who
subsequently re-developed positive cultures were
‘relapses’. Final treatment outcome was defined as
the composite ‘unfavourable’ clinical endpoint of
failure or relapse.
Vitamin D measurement
Serum samples were collected from each patient at
baseline, week 8 and the end of treatment, and stored
at 708C until analysis in a single batch. Briefly,
25(OH)D2 and D3 were extracted using zinc sulphate
and acetonitrile as precipitants. Samples were centri-
fuged to obtain a supernatant. Bio-analysis was
performed using reverse phase liquid chromatogra-
phy coupled to a tandemmass spectrometer in electro
spray ionisation positive mode. Quantification of
25(OH)D2 and 25(OH)D3 metabolites was based on
multiple reaction monitoring of the specific mass
transition for each target analyte. Total 25(OH)D
was the sum of (OH)D2 and (OH)D3 at each
timepoint. Holick’s definitions of vitamin D status
were used:22 hypovitaminosis D if 25(OH)D 675
nmol/l, vitamin D deficiency if 650 nmol/l, and
severe vitamin D deficiency if 625 nmol/l.
Sputum bacteriology
Baseline sputum samples were assessed using ZN and
auramine phenol smear microscopy17 to confirm
smear positivity, and were set up for culture using
solid media and liquid broth. For solid media, 1 ml of
undecontaminated sputum was homogenised with an
equal volume of dithiothreitol (Oxoid, Basingstoke,
UK), and five serial ten-fold dilutions were prepared
in phosphate buffered saline; 50 ll of neat sputum
and each dilution were plated onto duplicate plates of
Middlebrook 7H11 (BD, Sparks, MD, USA) oleic-
acid albumin agar media made selective by the
addition of polymyxin B (200 U/ml), ticarcillin (100
mg/l), trimethoprim (10 mg/l) and amphotericin B
(10–30 mg/l). After 3 weeks of incubation, visible
Mycobacterium tuberculosis colonies denoted posi-
tive cultures and dilutions yielding 10–100 colonies
were selected for counting. The baseline bacillary
load was the average log10 colony forming unit/ml of
sputum from duplicate plates of each sample.
One ml of each sputum sample was decontaminat-
ed using N-acetyl-L-cysteine/sodium hydroxide 3%
and inoculated into MGITe (Mycobacterial Growth
Indicator Tube, BD, Sparks, MD, USA). These were
placed in an incubator at 378C until they signalled
positive. The GenoTypewMTBDRplus 2.0 line-probe
assay (Hain Life Sciences, Nehren, Germany) con-
firmed that all M. tuberculosis isolates were RMP-
and INH-susceptible. Samples that did not signal
positive at 7 weeks were regarded as negative.
Sputum samples collected at 8 weeks, at end of
treatment and during post-treatment follow-up were
used to assess 2-month smear/culture conversion and
allocate final outcomes. All specimens were inoculat-
ed onto solid media and into broth, and were reported
as culture-positive if M. tuberculosis grew by either
method. Those with no growth in any media were
reported as negative.
Data analysis and statistical methods
Data were described using non-parametric summary
statistics. Multivariate linear regression was used to
assess factors contributing to variability in baseline
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serum 25(OH)D. A linear trapezoid rule was used to
calculate an area under the concentration time curve
(AUC0–6 months) for each patient, representing total
25(OH)D exposure during anti-tuberculosis treat-
ment. Logistic regression was used to study relation-
ships between baseline 25(OH)D and treatment
response (2-month smear or culture status and final
outcome). Relationships between changes from base-
line concentration during treatment or AUC0–6 months
and final outcome were also evaluated. Results of
linear and logistic regression analyses were expressed
as regression coefficients or odds ratios (ORs) with
95% confidence intervals (CIs). The Kruskal-Wallis
test was used to assess variability in baseline
25(OH)D at different recruitment months, and
AUC0–6 month variability among patients who initiat-
ed ART at different stages of anti-tuberculosis
treatment. Changes in 25(OH)D at different time-
points were analysed using paired Wilcoxon tests.
Significance was reported at P , 0.05.
Ethics
Ethics approval for this study was granted by the
Liverpool School of Tropical Medicine, Liverpool,
UK, and the College of Medicine Research Ethics
Committee, University of Malawi, Blantyre, Mala-
wi. Written informed consent was provided by all
participants.
RESULTS
Patients and outcomes
Baseline characteristics of the 169 patients recruited
are outlined in the Table. The median age was 31
years; 116 (69%) were male. The median body mass
index (BMI) was 18.4 kg/m2, and 33 (20%) patients
reported food insecurity (defined as regularly missing
more than one meal per day in the last month). Of the
169 patients, 52 (36%) had cavities on CXR; 98
(58%) were HIV-infected, with a median CD4 count
of 163 cells/ll.
Figure 1 shows patient retention and progress
through treatment of the study participants. At 8
weeks, 147 individuals remained in the study. For
those with sputum smear and culture results at this
time, 22/141 (16%) patients remained smear-positive
and 39/131 (30%) remained culture-positive. Over-
all, 133 patients remained in the study until allocation
of a final outcome: 118 (89%) achieved stable cure,
while 15 (11%) had unfavourable outcomes.
At baseline, 27/98 (33%)HIV-infected patientswere
undergoing ART. By study discharge, 64/76 (84%)
HIV-infected patients were undergoing ART. The ART
regimen among study completers was as follows: 57
(89%) received stavudine (d4T), lamivudine (3TC)
and nevirapine (NVP), 1 (2%) received zidovudine,
lamivudine and nevirapine, 3 (5%) received tenofovir
(TDF), 3TC and EFVand 3 (5%) were started on d4T,
3TC and NVP but switched to TDF, 3TC and EFV
during anti-tuberculosis treatment.
Vitamin D status at baseline
Baseline serum 25(OH)D concentrations were avail-
able for 166 patients, with a median value of 57
nmol/l: 29 (18%) patients had 25(OH)D within the
normal range and 72 (43%) had hypovitaminosis D;
65 (39%) had vitamin D deficiency, 18 (11%) of
whom had severe deficiency. The distribution of
25(OH)D measurements throughout the study pop-
ulation is shown in Figure 2.
The Table and Figure 3 show that, on multivariate
analysis, the strongest factor associated with baseline
vitamin D status was the month of recruitment;
participants recruited in July/August or September/
October had lower serum 25(OH)D than those
recruited in January/February (P ¼ 0.001 and P ¼
0.004, respectively). Lower 25(OD) also occurred in
patients with food insecurity (P ¼ 0.034) and those
who regularly consumed alcohol (P ¼ 0.019). There
were trends towards lower concentrations in patients
with lower BMI (P¼ 0.055) or who cooked indoors
with biomass fuel (P ¼ 0.066), but no relationships
between vitamin D status and HIV infection param-
eters, CXR cavitation or baseline bacillary load.
Figure 4 illustrates that, on univariate analysis,
there was no significant relationship between baseline
25(OH)D and the likelihood of a positive 2-month
sputum smear (OR 0.98, 95%CI 0.96–1.00, P ¼
0.129) or a positive 2-month sputum culture (OR
0.99, 95%CI 0.97–1.01, P ¼ 0.231). Surprisingly,
there was a slight trend towards unfavourable final
outcomes at higher baseline 25(OH)D (OR 1.02,
95%CI 1.00–1.05, P¼ 0.097). As the effect size was
very small and statistical significance was not
reached, it is unlikely that this was clinically relevant.
When vitamin D status was analysed as a categorical
variable with cut-offs at 25, 50 or 75 nmol/l, there
were no associations with any markers of treatment
response (data not shown). Multivariate models were
also constructed to establish whether incorporation
of other variables from the Table influenced response
to treatment. Although advancing age (OR 1.12,
95%CI 1.03–1.22, P ¼ 0.008) was independently
associated with positive 2-month sputum smears, all
multivariate models were consistent with the conclu-
sion from Figure 4 that there were no significant
relationships between 25(OH)D concentrations and
treatment response.
Vitamin D status during anti-tuberculosis treatment
Trends in serum 25(OH)D concentration over time
were assessed for the 133 patients who reached a final
outcome. Median serum 25(OH)D rose to 62 nmol/l
by week 8 of treatment and 64 nmol/l by end of
treatment (Figure 5). This occurred despite daily
administration of RMP and INH to all patients and
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increased use of ART by HIV-infected participants.
Figure 6 shows that 25(OH)D AUC0–6 months was not
influenced by HIV status or time of ART initiation.
There was insufficient use of ART regimens other
than d4T, 3TC and NVP to establish whether
different drug combinations influenced 25(OH)D
exposure during treatment.
Figure 4 demonstrates that change from baseline
25(OH)D concentration at 8 weeks (OR 1.00, 95%CI
0.97–1.04, P¼0.809) or end of treatment (OR 0.991,
95%CI 0.97–1.02, P¼0.490) was not associated with
final outcome, nor was 25(OH)D AUC0–6 months (OR
1.00, 95%CI 0.99–1.00, P¼ 0.213).
DISCUSSION
The role of vitamin D in anti-tuberculosis treatment
has been subject to prolonged debate. Our data
show that in a resource-poor population with high
rates of baseline vitamin D deficiency, variability in
serum 25(OH)D concentrations did not influence
treatment response.
The rate of vitamin D deficiency (39%) among TB
patients in our study was slightly lower than that
described previously at the same centre in Malawi
(42%).2 However, the previous study only recruited
patients in July, while we recruited all year round, and
our vitamin D deficiency rate for July/August was
much higher, at 70%. Although the number of
daylight hours in Malawi does not change between
seasons, a temperature drop from May to August
reduces sunlight exposure, as people remain indoors
Figure 1 Patient retention, progress and outcomes.* 8-week
sputum smear results available for 141 patients.† 8-week
sputum culture results available for 131 patients.‡ Unfavourable
outcomes ¼ failures at end of treatment (n ¼ 10) þ post-
treatment relapses (n ¼ 5). HIV ¼ human immunodeficiency
virus; ART¼antiretroviral therapy; TB¼ tuberculosis.
Figure 2 Histogram of baseline serum 25(OH)D concentra-
tions. Of 166 patients with serum 25(OH)D concentrations
measured at baseline, 29 (18%) had results within the normal
range and 72 (43%) had hypovitaminosis D; 65 (39%) had
vitamin D deficiency, 18 (11%) of whom had severe deficiency.
Figure 3 Effect of seasonality on baseline serum 25(OH)D
concentration. Serum 25(OH)D concentrations from the 166
patients with baseline data were lower in study participants
recruited during or just after the cold season. The P value
showing seasonal differences in serum 25(OH)D concentrations
was derived from the Kruskal-Wallis test.
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and wear additional layers of clothing. Data from
other settings indicate that vitamin D levels drop 1
month after a change in exposure to ultraviolet
rays,23–25 and our results are consistent with this.
Future studies in Malawi should take account of
seasonal periodicity.
Other than month of recruitment, most factors
linked to baseline 25(OH)D variability were related
to dietary or social circumstances (food insecurity,
alcohol consumption, low BMI and cooking indoors
with biomass fuel). Clinical factors, including HIV
status, baseline bacillary load or radiological extent
of disease, were not implicated. This broadly corrob-
orates other reports,3,24,26,27 and suggests that
environmental conditions are the key drivers of
vitamin D deficiency.
Overall, vitamin D deficiency rates reported in
Malawi are higher than those described in TB patient
cohorts in Guinea-Bissau (8.5%),28 but lower than
those reported in South Africa (80%).24 This degree
of regional variation underlines the need for caution
when extrapolating results of vitamin D studies
between African settings.
No analysis of serum 25(OH)D concentrations
described a significant relationship between vitamin
D status and sputum smear or culture positivity at 2
months or final outcome. This contrasts with
previous data from Tanzania, which reported that
lower baseline 25(OH)D concentrations were associ-
ated with post-treatment relapse.13 The reasons for
this are unclear, but the overall unfavourable out-
come rate was higher in Tanzania (19% vs. 11% in
our study), suggesting that there were underlying
differences between the cohorts. Furthermore, the
Tanzanian cohort had higher baseline 25(OH)D
concentrations (median 70 vs. 57 nmol/l), and the
main outcome difference was between patients with
levels .75 vs. 675 nmol. It is possible that we
recruited an insufficient number of patients with
25(OH)D concentrations .75 nmol/l threshold to
detect the advantage experienced by this group.
However, the results of our study support three
clinical trials that showed no benefit of vitamin D
supplementation during anti-tuberculosis treatment,
despite significant elevation in 25(OH)D concentra-
tions among patients who received supplements.10–12
Figure 4 Variability in serum 25(OH)D concentrations by response to anti-tuberculosis treatment: A–C) difference in baseline serum
25(OH)D concentration by 2-month sputum smear status (n ¼ 141), 2-month sputum culture status (n ¼ 131) and final clinical
outcome (n ¼ 133), respectively; D) changes in 25(OH)D concentration from baseline to 8 weeks; E) changes in 25(OH)D
concentration from baseline to end of treatment by clinical outcome (n¼133); F) 25(OH)D exposure across the duration of treatment,
represented by the area under the concentration time curve by clinical outcome (n ¼ 133). All P values are derived from logistic
regression analysis.
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It is reassuring to note that 25(OH)D concentra-
tions increased over time, despite previous reports
that RMP, INH and some ART drugs may reduce the
bioavailability of active vitamin D metabolites.
Improved 25(OH)D concentrations during the course
of anti-tuberculosis treatment were also observed in a
study in Tanzania.29 We propose that increased
dietary intake and outdoor activity during recovery
from TB contributes to improved vitamin D levels,
and adequately compensates any deleterious drug
effects on metabolism. It is not possible to definitively
confirm this hypothesis with our data, but it does
appear that routine 25(OH)D supplementation is not
required to prevent exacerbation of baseline deficien-
cy in our setting.
There were several limitations to this work. As
only patients with sputum culture-positive TB were
included, no comment can be made about vitamin D
levels in extra-pulmonary disease. The vitamin D
receptor genotype of our patients was unknown, and
one clinical trial has suggested that individuals with
the tt genotype of the TaqI receptor polymorphism
are more likely to respond to vitamin D supplemen-
tation.30 National ART protocols during the study
dictated that most patients did not receive EFV, a
Figure 5 Serum 25(OH)D concentration during anti-tuberculosis treatment. Data only shown for the 133 patients who completed
the study. Serum 25(OH)D concentrations gradually increased over time on anti-tuberculosis treatment. Differences between
measurements at different times were analysed using paired Wilcoxon tests. R ¼ rifampicin; H ¼ isoniazid; Z ¼ pyrazinamide; E ¼
ethambutol; HIV¼ human immunodeficiency virus; ART¼antiretroviral therapy.
Figure 6 Changes in serum 25(OH)D concentration from
baseline to end of treatment in HIV patients by timing of ART
initiation. Data only shown for the 133 patients who completed
the study. There was no difference in total 25(OH)D exposure, as
measured by total time under the concentration-time curve
between non-HIV-infected patients and HIV-infected patients,
irrespective of the timing of ART initiation during anti-
tuberculosis treatment. The P value was derived by the
Kruskal-Wallis test. HIV ¼ human immunodeficiency virus; ART
¼ antiretroviral therapy; TB¼ tuberculosis.
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drug previously associated with vitamin D deficien-
cy.16 First-line ART recommendations for TB pa-
tients have since changed, and it is possible that the
effect of ART on vitamin D metabolism varies by
treatment regimen.
CONCLUSIONS
Vitamin D deficiency remains common among new
pulmonary TB patients in Malawi. Social and envi-
ronmental factors, particularly seasonality, are the
main drivers of variability in vitamin D status but this
variability does not influence treatment response. Any
adverse pharmacological effects of anti-tuberculosis
and ART drugs on bioavailability of 25(OH)D are
compensated by the positive effects of clinical recovery.
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R E S U M E
CONT EX T E : Le de´ficit en vitamine D est fre´quent chez
les adultes africains atteints de tuberculose (TB), et il
peut eˆtre exacerbe´ par les effets me´taboliques des
me´dicaments antituberculeux et par la the´rapie
antire´trovirale (ART). On ne sait pas vraiment si le
de´ficit en vitamine D influence la re´ponse au traitement
de la TB.
OB J E C T I F : De´crire les facteurs de risque du de´ficit en
vitamine D initial chez des adultes du Malawi atteints de
TB pulmonaire, e´valuer la relation entre la
concentration se´rique en 25 hydroxyvitamine D
(25[OH]D) et la re´ponse au traitement et e´valuer si
l’administration de me´dicaments antituberculeux et
l’ART ont un effet ne´gatif sur le statut de la vitamine
D au cours du traitement.
S CH E´MA : Etude de cohorte prospective longitudinale.
R E´ S U LTAT S : Ont e´te´ recrute´s 169 patients (58%
infecte´s par le virus de l’immunode´ficience humaine
[VIH]). La concentration me´diane initiale du 25(OH)D
a e´te´ de 57nmol/l ; 47 (28%) patients ont eu un re´sultat
,50 nmol/l, c’est-a`-dire, un de´ficit en vitamine D. Les
concentrations initiales de 25(OH)D ont e´te´ plus faibles
pendant la saison froide (P , 0,001), avec l’inse´curite´
alimentaire (P ¼ 0,034) ou chez des patients qui
consommaient de l’alcool (P ¼ 0,019). Il n’y a pas eu
de relation entre le statut en vitamine D et la re´ponse au
traitement de la TB. Les concentrations de 25(OH)D se
sont accrues durant la the´rapie antituberculeuse, quel
que soit le statut VIH ou le recours a` l’ART.
C O N C L U S I O N S : Le de´ficit en vitamine D est
fre´quent chez les patients tuberculeux au Malawi,
mais il n’influence pas la re´ponse au traitement. Les
effets secondaires me´taboliques des traitements
me´dicamenteux pourraient eˆtre compense´s par
l’impact positif de la gue´rison clinique qui pre´vient
une aggravation du de´ficit en vitamine D pendant le
traitement de la TB.
R E S UM E N
MARCO DE R E F E R ENC I A: La deficiencia de vitamina D
es frecuente en los adultos que padecen tuberculosis
(TB) en A´frica y su exacerbacio´n puede ser la
consecuencia de efectos metabo´licos provocados por
los medicamentos antituberculosos y el tratamiento
antirretrovı´rico (ART). No es claro si esta deficiencia
vitamı´nica influye sobre la respuesta al tratamiento de la
TB.
OB J E T I VO S: Describir los factores de riesgo de los
pacientes adultos con TB pulmonar en Malawi de
sufrir una deficiencia de vitamina D al comienzo del
estudio, evaluar la correlacio´n entre la concentracio´n
se´rica de 25 hidroxi-vitamina D (25[OH]D) y la
respuesta al tratamiento y analizar si la administracio´n
de medicamentos antituberculosos o ART altera el
estado de la vitamina D durante el tratamiento.
M E´ TODO: Fue este un estudio de cohortes longitudinal
prospectivo.
R E S U LTA D O S: Participaron en el estudio 169
pacientes (58% con coinfeccio´n por el virus de la
inmunodeficiencia humana [VIH]). La mediana de la
concentracio´n se´rica de 25(OH)D al comienzo del estudio
fue 57 nmol/l. Se encontro´ deficiencia de vitamina D en
47 pacientes (28%; ,50 nmol/l). Las concentraciones
se´ricas de base fueron ma´s bajas durante la temporada
frı´a (P , 0,001), cuando existı´a inseguridad alimentaria
(P¼0,034) o en los pacientes que consumı´an alcohol (P¼
0,019). No se observo´ una correlacio´n entre la
concentracio´n de la vitamina D y la respuesta al
tratamiento antituberculoso. Las concentraciones se´ricas
de 25(OH)D aumentaron durante el tratamiento
antituberculoso, independientemente de la situacio´n
frente al VIH o la administracio´n del ART.
C O N C L U S I O´ N: La deficiencia de vitamina D es
frecuente en los pacientes con diagno´stico de TB en
Malawi, pero esta carencia no afecta su respuesta
al tratamiento. Los efectos metabo´licos de los
medicamentos se compensan con el efecto positivo de
la recuperacio´n clı´nica, lo cual evita una exacerbacio´n de
la deficiencia vitamı´nica durante el tratamiento de la
TB.
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